

## Supplementary Results

The *SLC35A2* gene has been previously associated with mild MCD or FCD type 1<sup>1,2</sup> but was more recently confirmed as a genetic marker for the MOGHE phenotype.<sup>3-5</sup> We originally identified four FCD 1a or mMCD samples with *SLC35A2* variants. However, upon in-depth review of histopathological imaging, we determined that the pathological phenotypes of these samples more closely matched MOGHE and reclassified them accordingly. Thus, we detected alterations in *SLC35A2* exclusively in MOGHE samples. Accordingly, we observed a strong association between *SLC35A2* and MOGHE, with 47.1% (16/35) of MOGHE samples carrying a variant in *SLC35A2*.

As expected, alterations in *FGFR1* were exclusively identified in DNET (29%, 7/24), with multiple alterations identified in the majority of cases (71%, 5/7 *FGFR1*-DNET).<sup>6,7</sup> Variants in *BRAF* were strongly associated with ganglioglioma<sup>8</sup>, with 77.6% (52/67) of detected *BRAF* alterations occurring in ganglioglioma and 57.5% (46/80) of ganglioma carrying at least one alteration in *BRAF*. Of these, the majority (40/46, 87%) carried the *BRAFV600E* variant. Furthermore, *BRAFV600E* was detected in all three pleomorphic xanthoastrocytoma<sup>7</sup> samples in our cohort. Of note, we observed six ganglioglioma with both a somatic *BRAF* SNV and a somatic duplication covering the *BRAF* gene (7.5%), one sample with two separate somatic duplications covering *BRAF*, and one sample with two different SNV in *BRAF* (V600E and A764V).

Our gene enrichment analysis revealed a strong association between LEAT and *PTPN11* (Figure 3). Our somatic variant gene discovery also revealed novel associations between epileptogenic brain lesions and two different RAS genes, *NRAS* and *KRAS*. Alterations in *NRAS* showed a strong association with polymicrogyria (PMG) and were exclusively detected in 17% of PMG (2/12). We detected a singular somatic *KRAS* SNV in a cancer driving site in a case of meningioangiomas (50%, 1/2), a lesion typically associated with the germline neurofibromatosis 2, but not somatic variants in *NF2*.<sup>9,10</sup> To the best of our knowledge, we are the first to report an association between RAS genes and epileptogenic lesions. Lastly, we identified an association between somatic alterations in *NFI* and epileptogenic brain lesions. We detected nine *NFI* alterations across seven LEAT, which included two ganglioglioma, two DNET, and three gliomas (Fig 3A). Among these, we identified DNET sample carrying two distinct somatic *NFI* SNV (a splicing variant and a stopgain) and a pilocytic astrocytoma carrying a somatic *NFI* PTV and a somatic CNN-LOH covering *NFI*. We also identified an additional seven *NFI* alterations across five MCD, which

included four FCD II and a single PMG (Fig 3A). From these, we only detected more than one variant in the PMG, which carried three distinct *NFI* alterations (T30K, G26X, and a somatic CNN-LOH covering *NFI*). Our results expand the spectrum of epileptogenic brain lesions associated to variants in the canonical RAS-RAF-MAPK pathway and serve as a foundation for untangling the role of this pathway in lesional epilepsies.

Supplementary Table 1: Top hits from gene enrichment analysis

Gene	Synonymous variants	Missense variants	Nonsense variants	Splice variants	Insertions/deletions	$P_{\text{global}}$ (unadjusted)	$Q_{\text{global}}$
<b>Hippocampal Sclerosis (n=97)</b>							
<i>NUDT14</i>	0	0	0	0	1	0.001052	1
<i>TEX45</i>	0	0	0	0	1	0.001724	1
<i>FKBP10</i>	0	0	0	0	1	0.001858	1
<i>ARNT</i>	0	0	0	0	1	0.00216	1
<i>UNC5C</i>	0	0	0	0	1	0.002331	1
<b>Malformations of cortical development (n=223)</b>							
<i>SLC35A2</i>	0	7	2	0	3	0	<b>0</b>
<i>MTOR</i>	0	11	0	0	1	2.56E-10	<b>2.57E-06</b>
<i>AKT3</i>	0	3	0	0	0	3.47E-04	1
<i>OR9G1</i>	0	4	0	0	0	7.59E-04	1
<i>OR9G9</i>	0	4	0	0	0	7.59E-04	1
<i>NRAS</i>	0	2	0	0	0	0.002669	1
<i>CD3G</i>	0	0	0	0	1	0.003661	1
<b>Low-grade epilepsy-associated tumors (n=154)</b>							
<i>BRAF</i>	0	39	0	0	3	0	<b>0</b>
<i>PTPN11</i>	0	6	0	0	0	4.19E-08	<b>4.21E-04</b>
<i>FGFR1</i>	0	4	0	0	0	2.62E-05	0.175515
<i>OR4C3</i>	0	4	0	0	0	3.16E-04	1
<i>AURKC</i>	0	1	0	0	1	3.59E-04	1
<i>NF1</i>	0	0	0	0	2	7.76E-04	1
<i>RARA</i>	0	1	0	0	1	0.001494	1
<i>HSPA2</i>	0	1	0	0	1	0.002737	1
<i>GNRH2</i>	0	0	0	0	1	0.004502	1

**Supplementary Table 2: Identified cancer drivers**

<b>Gene</b>	<b>Known driver site</b>	<b>Samples with variants</b>	<b>Associated pathology</b>	<b>Specific sample pathologies</b>
<i>BRAF</i>	p.V600	45	LEAT	Ganglioglioma, PXA, MVNT
<i>MTOR</i>	p.S2215	3	MCD	FCD type IIb, HME
	p.T1977	1	MCD	FCD type IIb
	p.L1460	1	MCD	FCD type IIb
<i>NRAS</i>	p.Q61	2	MCD	PMG
<i>PTPN11</i>	p.A72	2	LEAT	DNET
	p.E76	1	LEAT	Ganglioglioma
<i>KRAS</i>	p.G12	1	LEAT	Meningioangiomas
<i>PIK3CA</i>	p.V344	1	LEAT	DNET
	p.E545	1	MCD	HME

**Legend:** PXA = Pleomorphic xanthoastrocytoma, MVNT = Multinodular vacuolated neuronal tumor, FCD = Focal cortical dysplasia, HME = Hemimegalencephaly, PMG = Polymicrogyria, DNET = Dysembryoplastic Neuroepithelial tumor

**Supplementary table 3: Phenotypic review of genetic-positive samples**

Sample name	Lesion category	Original pathology	Genetic diagnosis	Revised pathology	Additional information	Conclusion after histopathological review
MCD_EEBB_26	MCD	HME	<i>PIK3CA</i>	Complex MCD	HME / PMG / FCD 2a	phenotype refinement
MCD_EEBB_57	MCD	HME	<i>AKT3, MTOR</i>	Complex MCD	HME / PMG / FCD 2a	phenotype refinement
MCD_EEBB_52	MCD	HME	<i>PIK3CA</i>	Complex MCD	HME / PMG / FCD 2a	phenotype refinement
MCD_EEBB_10	MCD	PMG	<i>NRAS</i>	Complex MCD	PMG / NH / FCD 2a / GG	phenotype refinement
MCD_EEBB_89	MCD	PMG	<i>NF1</i> SNV + CNN-LOH	Complex MCD	PMG / FCD 1b	phenotype refinement
MCD_EEBB_65	MCD	PMG	<i>NRAS</i>	Complex MCD	PMG / NH / FCD 2a / DNET	phenotype refinement
MCD_EEBB_21	MCD	PMG	<i>PIK3CA</i>	Complex MCD	HME / PMG / FCD 2a	reclassification
MCD_CCF_93	MCD	FCD (NOS)	<i>AKT3</i>	Complex MCD	HME / PMG / FCD 2a	reclassification
MCD_CCF_94	MCD	FCD (NOS)	<i>PTEN</i> SNV + CNN-LOH	Complex MCD	HME / PMG / FCD 2a / FCD 1a	reclassification
MCD_CCF_110	MCD	FCD (NOS)	<i>AKT3</i>	Complex MCD	HME / PMG / FCD 2a	reclassification
MCD_CCF_32	MCD	FCD (NOS)	<i>NPRL3</i>	Complex MCD	PMG / FCD 2a / FCD 1a	reclassification
MCD_CCF_104	MCD	FCD (NOS)	<i>MTOR, TSC2</i> SNV + CNN-LOH	Complex MCD	PMG / FCD 2b	reclassification
MCD_CCF_92	MCD	FCD (NOS)	<i>MTOR</i>	FCD 2b		reclassification
MCD_CCF_101	MCD	FCD (NOS)	<i>MTOR</i>	FCD 2b		reclassification
MCD_CCF_29	MCD	FCD (NOS)	<i>TSC2</i>	Cortical tuber	FCD 2b	reclassification
MCD_CCF_55	MCD	FCD (NOS)	<i>TSC2</i>	Cortical tuber	FCD 2b	reclassification
MCD_CCF_56	MCD	FCD (NOS)	<i>TSC2</i>	Cortical tuber	FCD 2b	reclassification
MCD_CCF_27	MCD	FCD 2b	<i>TSC2</i>	Cortical tuber	FCD 2b	reclassification
MCD_EEBB_76	MCD	FCD 2b	<i>MTOR</i>	Complex MCD	PMG / FCD 2b	reclassification
MCD_EEBB_68	MCD	FCD 2b	<i>DEPDC5</i> CNN-LOH	FCD 2a		reclassification
MCD_CCF_62	MCD	FCD 2a	Chr 1q gain	FCD 2a	Hyaline astrocytic inclusions	phenotype refinement
MCD_EEBB_110	MCD	MOGHE	Chr 1q gain	FCD 2a	Hyaline astrocytic inclusions	reclassification
MCD_CCF_30	MCD	mMCD	<i>DEPDC5</i>	FCD 2a		reclassification
MCD_CCF_80	MCD	mMCD	<i>DEPDC5</i>	FCD 2a		reclassification
MCD_EEBB_100	MCD	mMCD	<i>SLC35A2</i>	MOGHE		reclassification
MCD_CCF_79	MCD	FCD 1a	<i>SLC35A2</i>	MOGHE		reclassification
MCD_EEBB_58	MCD	FCD 1a	<i>SLC35A2</i>	MOGHE		reclassification
MCD_EEBB_87	MCD	FCD 1a	<i>SLC35A2</i>	MOGHE		reclassification
MCD_CCF_77	MCD	FCD 1a	<i>DEPDC5</i>	MOGHE	FCD 1a	reclassification
LEAT_CCF_6	LEAT	LEAT (NOS)	<i>PTPN11</i>	DNET		reclassification
LEAT_CCF_37	LEAT	LEAT (NOS)	Chr7 gain, <i>TSC2</i> (somatic) SNV + CNN-LOH	Subependymal giant cell astrocytoma		reclassification

Legend to supplementary table 3: MCD = Malformation of cortical development, LEAT = Low-grade epilepsy-associated tumor, FCD = Focal cortical dysplasia, NOS = Not otherwise specified, HME = Hemimegalencephaly, PMG = Polymicrogyria, mMCD = mild MCD, MOGHE = mMCD with oligodendroglial hyperplasia in epilepsy, NH = nodular heterotopia, DNET = Dysembryoplastic neuroepithelial tumor, IDA = Isomorphic diffuse astrocytoma, PXA = Pleomorphic xanthoastrocytoma, MVNT = multinodular vacuolated neuronal tumor, SEGA = Subependymal giant cell astrocytoma, GG = Ganglioglioma, CNN-LOH = Copy number neutral loss of heterozygosity

**Supplementary Table 4: Reported SNV in 19 lesional epilepsy genes**

Sample	Sex	Age at onset	Age at surgery	Lesion group	Pathology	Additional findings	Gene	Variant position(hg19)	Transcript ID	cDNA change	Amino acid change	Variant class	Allelic fraction
HS_EEBB_20	F	0-4	45-49	HS	HS Type I	FCD 3a	<i>MTOR</i>	chr1:11188137	NM_004958	c.C5957G	p.A1986G	Missense	0.47
HS_EEBB_41	F	0-4	35-39	HS	HS Type I		<i>PTPNI1</i>	chr12:112926885	NM_002834	c.C1505T	p.S502L	Missense	0.02
HS_EEBB_53	M	0-4	45-49	HS	HS Type I		<i>TSC1</i>	chr9:135772010	NM_000368	c.G3107A	p.G1036E	Missense	0.50
HS_EEBB_71	M	45-49	70-74	HS	HS Type I		<i>MTOR</i>	chr1:11301631	NM_004958	c.C1520T	p.P507L	Missense	0.47
HS_EEBB_17	M	20-24	25-29	HS	HS Type 2	FCD 3a	<i>PTEN</i>	chr10:89720649	NM_001304717	c.1321-2A>T	Splicing	PTV	0.03
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.17
LEAT_EEBB_10	F	5-9	15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.15
LEAT_EEBB_10	F	5-9	15-19	LEAT	Ganglioglioma		<i>PTPNI1</i>	chr12:112888210	NM_002834	c.G226A	p.E76K	Missense	0.02
LEAT_EEBB_100	M	10-14	15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.17
LEAT_EEBB_100	M	10-14	15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140426307	NM_001354609	c.C2291T	p.A764V	Missense	0.03
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.36
LEAT_EEBB_106	F	0-4	30-34	LEAT	Ganglioglioma	HS Type I	<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_107	M	0-4	5-9	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_108	F	5-9	5-9	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.05
LEAT_EEBB_12	M	0-4	0-4	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.10
LEAT_EEBB_14	M		15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_15	M	15-19	15-19	LEAT	Ganglioglioma	HS	<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.13
LEAT_EEBB_15	M	15-19	15-19	LEAT	Ganglioglioma	HS	<i>PTPNI1</i>	chr12:112888165	NM_002834	c.G181A	p.D61N	Missense	0.03
LEAT_EEBB_15	M	15-19	15-19	LEAT	Ganglioglioma	HS	<i>PTPNI1</i>	chr12:112891083	NM_002834	c.G417C	p.E139D	Missense	0.03
LEAT_EEBB_22	M		0-4	LEAT	Ganglioglioma	HS Type I	<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.09
LEAT_EEBB_22	M		0-4	LEAT	Ganglioglioma	HS Type I	<i>NFI</i>	chr17:29579966	NM_001042492	c.A4121G	p.H1374R	Missense	0.44
LEAT_EEBB_22	M		0-4	LEAT	Ganglioglioma	HS Type I	<i>TSC2</i>	chr16:2130303	NM_000548	c.G3535A	p.E1179K	Missense	0.44
LEAT_EEBB_27	M	15-19	15-19	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.15
LEAT_EEBB_32	F	20-24	20-24	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453137	NM_004333	c.1798delinsACAG	p.T599_V600insT	Missense	0.26
LEAT_EEBB_34	M		0-4	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.19
LEAT_EEBB_37	M	0-4	40-44	LEAT	Ganglioglioma	HS Type I	<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_39	F	0-4	25-29	LEAT	Ganglioglioma		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12

LEAT_EEBB_40	F	10-14	25-29	LEAT	Ganglioglioma	HS Type 1	BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.20
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.08
LEAT_EEBB_43	F	0-4	0-4	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.25
LEAT_EEBB_44	M	0-4	0-4	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_47	F	0-4	0-4	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.08
LEAT_EEBB_52	M	10-14	20-24	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.09
LEAT_EEBB_53	F	10-14	15-19	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_54	M	0-4	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.18
LEAT_EEBB_57	M	0-4	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.13
LEAT_EEBB_61	M	0-4	0-4	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.15
LEAT_EEBB_62	M	45-49	45-49	LEAT	Ganglioglioma		TSC1	chr9:135772994	NM_000368	c.G2629T	p.V877L	Missense	0.03
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12
LEAT_EEBB_65	M	0-4	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.23
LEAT_EEBB_67	M		5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12
LEAT_EEBB_73	M	0-4	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.14
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.14
LEAT_EEBB_76	F	5-9	15-19	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.16
LEAT_EEBB_78	M	0-4	5-9	LEAT	Ganglioglioma	HS Type 1	BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.04
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.19
LEAT_EEBB_84	M	0-4	0-4	LEAT	Ganglioglioma	HS Type 2	BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.21
LEAT_EEBB_84	M	0-4	0-4	LEAT	Ganglioglioma	HS Type 2	PIK3CA	chr3:178942554	NM_006218	c.C2361A	p.D787E	Missense	0.47
LEAT_EEBB_85	M		30-34	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.13
LEAT_EEBB_90	F		45-49	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.06
LEAT_EEBB_90	F		45-49	LEAT	Ganglioglioma		PTEN	chr10:89720649	NM_001304717	c.1321-2A>T	Splicing	PTV	0.06
LEAT_EEBB_91	F	5-9	10-14	LEAT	Ganglioglioma		BRAF	chr7:140477841	NM_004333	c.1465_1467delinsA	p.A489Tfs*12	PTV	0.03
LEAT_EEBB_94	M	5-9	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.41
LEAT_EEBB_96	M	5-9	5-9	LEAT	Ganglioglioma	HS Type 1	BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.11
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12
LEAT_EEBB_99	F	0-4	5-9	LEAT	Ganglioglioma		BRAF	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12
LEAT_CCF_6	F	30-34	30-34	LEAT	DNET		PTPN11	chr12:112926900	NM_002834	c.C1520A	p.T507K	Missense	0.02

LEAT_EEBB_105	F	35-39	35-39	LEAT	DNET		<i>FGFR1</i>	chr8:38272308	NM_001174067	c.A2059G	p.K687E	Missense	0.18
LEAT_EEBB_105	F	35-39	35-39	LEAT	DNET		<i>FGFR1</i>	chr8:38274850	NM_001174067	c.A1730G	p.N577S	Missense	0.11
LEAT_EEBB_105	F	35-39	35-39	LEAT	DNET		<i>NFI</i>	chr17:29554604	NM_001042492	c.2389delG	p.A797Pfs*24	PTV	0.04
LEAT_EEBB_33	M	10-14	15-19	LEAT	DNET		<i>PIK3CA</i>	chr3:178952085	NM_006218	c.A3140G	p.H1047R	Missense	0.03
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		<i>FGFR1</i>	chr8:38274849	NM_001174067	c.C1731A	p.N577K	Missense	0.18
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		<i>NFI</i>	chr17:29665035	NM_001042492	c.6705-8_6705-1delinsA	Splicing	PTV	0.05
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		<i>NFI</i>	chr17:29552151	NM_001042492	c.C1884G	p.Y628X	PTV	0.05
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		<i>PTPN11</i>	chr12:112888199	NM_002834	c.C215T	p.A72V	Missense	0.03
LEAT_EEBB_6	M	10-14	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272308	NM_001174067	c.A2059G	p.K687E	Missense	0.42
LEAT_EEBB_6	M	10-14	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272308	NM_001174067	c.A2059C	p.K687Q	Missense	0.42
LEAT_EEBB_6	M	10-14	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272319	NM_001174067	c.A2048G	p.D683G	Missense	0.41
LEAT_EEBB_60	M	15-19	20-24	LEAT	DNET		<i>FGFR1</i>	chr8:38272308	NM_001174067	c.A2059G	p.K687E	Missense	0.04
LEAT_EEBB_60	M	15-19	20-24	LEAT	DNET		<i>FGFR1</i>	chr8:38272322	NM_001174067	c.T2045C	p.I682T	Missense	0.03
LEAT_EEBB_81	M	45-49	55-59	LEAT	DNET		<i>FGFR1</i>	chr8:38274849	NM_001174067	c.C1731A	p.N577K	Missense	0.23
LEAT_EEBB_81	M	45-49	55-59	LEAT	DNET		<i>PTPN11</i>	chr12:112888199	NM_002834	c.C215G	p.A72G	Missense	0.02
LEAT_EEBB_83	M	5-9	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272302	NM_001174067	c.A2065C	p.T689P	Missense	0.31
LEAT_EEBB_83	M	5-9	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272307	NM_001174067	c.A2060T	p.K687M	Missense	0.30
LEAT_EEBB_83	M	5-9	10-14	LEAT	DNET		<i>FGFR1</i>	chr8:38272321	NM_001174067	c.C2046G	p.I682M	Missense	0.30
LEAT_EEBB_83	M	5-9	10-14	LEAT	DNET		<i>PIK3CA</i>	chr3:178921549	NM_006218	c.T1031G	p.V344G	Missense	0.03
LEAT_EEBB_2	F		35-39	LEAT	Angiocentric glioma		<i>DEPDC5</i>	chr22:32206593	NM_001242896	c.G1411A	p.G471S	Missense	0.54
LEAT_EEBB_31	M	10-14	10-14	LEAT	MA	FCD 3c	<i>KRAS</i>	chr12:25398284	NM_033360	c.G35A	p.G12D	Missense	0.05
LEAT_EEBB_113	M	0-4	44-49	LEAT	MVNT		<i>BRAF</i>	chr7:140453138	NM_004333	c.1797delinsTACA	p.T599_V600insT	Missense	0.14
LEAT_EEBB_95	F	5-9	35-39	LEAT	Pilocytic Astrocytoma		<i>NFI</i>	chr17:29677325	NM_001042492	c.7446_7450delinsC	p.S2484ifs*4	PTV	0.13
LEAT_EEBB_38	M	10-14	15-19	LEAT	PXA		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.12
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.41
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		<i>NFI</i>	chr17:29559097	NM_001042492	c.G3204T	p.L1068F	Missense	0.28
LEAT_EEBB_59	M		15-19	LEAT	PXA		<i>BRAF</i>	chr7:140453136	NM_004333	c.T1799A	p.V600E	Missense	0.22
LEAT_CCF_37	M	0-4	5-9	LEAT	TSC	SEGA	<i>TSC2</i>	chr16:2106223	NM_000548	c.626_628delinsC	p.A210Vfs*24	PTV	0.02
LEAT_EEBB_17	F	0-4	5-9	LEAT	TSC	SEGA	<i>PTPN11</i>	chr12:112888165	NM_002834	c.G181C	p.D61H	Missense	0.05



LEAT_EEBB_17	F	0-4	5-9	LEAT	TSC	SEGA	TSC2	chr16:2106719	NM_000548	c.724dupA	p.T242Nfs*96	PTV	0.46
MCD_CCF_19	M	10-14	25-29	MCD	MOGHE		SLC35A2	chrX:48762551	NM_005660	c.632_635del	p.L211Pfs*137	PTV	0.05
MCD_CCF_43	M	0-4	5-9	MCD	MOGHE		SLC35A2	chrX:48762557	NM_005660	c.G629A	p.C210Y	Missense	0.05
MCD_CCF_77	F	0-4	0-4	MCD	MOGHE	FCD1a	DEPDC5	chr22:32161000	NM_001242896	c.G233C	p.R78P	Missense	0.40
MCD_CCF_79	F	0-4	0-4	MCD	MOGHE		SLC35A2	chrX:48763748	NM_005660	c.C347A	p.A116E	Missense	0.14
MCD_CCF_108	M	5-9	25-29	MCD	MOGHE		SLC35A2	chrX:48767173	NM_005660	c.192delinsACCGC	p.F65Pfs*30	PTV	0.24
MCD_EEBB_2	F	0-4	5-9	MCD	MOGHE		SLC35A2	chrX:48762251	NM_005660	c.C935T	p.S312F	Missense	0.08
MCD_EEBB_17	F	20-24	55-59	MCD	MOGHE		SLC35A2	chrX:48762671	NM_005660	c.T515C	p.L172P	Missense	0.03
MCD_EEBB_34	F	10-14	40-44	MCD	MOGHE		SLC35A2	chrX:48763729	NM_005660	c.366delinsTCTC	p.Y122_T123insL	Missense	0.09
MCD_EEBB_34	F	10-14	40-44	MCD	MOGHE		SLC35A2	chrX:48763730	NM_005660	c.364_365insC	p.Y122Sfs*6	PTV	0.15
MCD_EEBB_37	M	0-4	25-29	MCD	MOGHE		SLC35A2	chrX:48762518	NM_005660	c.665_668delinsT	p.K222del	Missense	0.29
MCD_EEBB_58	M	0-4	0-4	MCD	MOGHE		SLC35A2	chrX:48762239	NM_005660	c.921_947delinsT	p.S308Wfs*106	PTV	0.11
MCD_EEBB_63	M	0-4	5-9	MCD	MOGHE		SLC35A2	chrX:48762510	NM_005660	c.675dupA	p.G226Rfs*29	PTV	0.40
MCD_EEBB_69	F	15-19	40-44	MCD	MOGHE		SLC35A2	chrX:48762546	NM_005660	c.G640C	p.G214R	Missense	0.08
MCD_EEBB_87	F	0-4	5-9	MCD	MOGHE		SLC35A2	chrX:48763773	NM_005660	c.C322T	p.Q108X	PTV	0.09
MCD_EEBB_97	F	0-4	15-19	MCD	MOGHE		NPRL2	chr3:50385595	NM_006545	c.A892C	p.I298L	Missense	0.04
MCD_EEBB_97	F	0-4	15-19	MCD	MOGHE		SLC35A2	chrX:48762281	NM_005660	c.C905T	p.S302F	Missense	0.08
MCD_EEBB_100	M		5-9	MCD	MOGHE		SLC35A2	chrX:48763773	NM_005660	c.C322T	p.Q108X	PTV	0.25
MCD_EEBB_102	F	0-4	0-4	MCD	MOGHE		SLC35A2	chrX:48762251	NM_005660	c.C935T	p.S312F	Missense	0.12
MCD_EEBB_106	M	0-4	5-9	MCD	MOGHE		SLC35A2	chrX:48762354	NM_005660	c.C832T	p.Q278X	PTV	0.48
MCD_EEBB_22	F	5-9	25-29	MCD	FCD 1a		MTOR	chr1:11307914	NM_004958	c.C1078T	p.R360V	Missense	0.04
MCD_CCF_8	M	5-9	20-24	MCD	FCD 2a		NF1	chr17:29559092	NM_001042492	c.G3199T	p.D1067Y	Missense	0.25
MCD_CCF_13	M	0-4	20-24	MCD	FCD 2a		NF1	chr17:29654761	NM_001042492	c.C5513G	p.S1838C	Missense	0.43
MCD_CCF_13	M	0-4	20-24	MCD	FCD 2a		NPRL2	chr3:50386328	NM_006545	c.C562T	p.Q188X	PTV	0.53
MCD_CCF_30	M	0-4	15-19	MCD	FCD 2a		DEPDC5	chr22:32193632	NM_001242896	c.G814T	p.V272L	Missense	0.46
MCD_CCF_46	F	5-9	25-29	MCD	FCD 2a		NPRL3	chr16:142605	ENST00000399953	c.1149dupC	p.A384Rfs*71	PTV	0.50
MCD_CCF_58	F	0-4	0-4	MCD	FCD 2a		NPRL3	chr16:143291	ENST00000399953	c.G957A	p.W319X	PTV	0.56
MCD_CCF_60	F	0-4	0-4	MCD	FCD 2a		NPRL2	chr3:50388010	NM_006545	c.73dupT	p.Y25Lfs*5	PTV	0.57
MCD_CCF_80	F	45-49	55-59	MCD	FCD 2a		DEPDC5	chr22:32233122	NM_001242896	c.C2335G	p.P779A	Missense	0.49

MCD_CCF_83	F	0-4	5-9	MCD	FCD 2a		NPRL3	chr16:136827	ENST00000399953	c.1584delT	p.M529Cfs*23	PTV	0.48
MCD_EEBB_18	M	5-9	10-14	MCD	FCD 2a		BRAF	chr7:140549970	NM_004333	c.A181G	p.L61V	Missense	0.42
MCD_EEBB_56	M	0-4	0-4	MCD	FCD 2a		NPRL3	chr16:143268	ENST00000399953	c.C980T	p.P327L	Missense	0.42
MCD_EEBB_75	M	0-4	10-14	MCD	FCD 2a		DEPDC5	chr22:32239185	NM_001242896	c.C2620T	p.R874X	PTV	0.43
MCD_EEBB_86	M	15-19	40-44	MCD	FCD 2a		MTOR	chr1:11217230	NM_004958	c.G4448A	p.C1483Y	Missense	0.05
MCD_EEBB_88	M	0-4	5-9	MCD	FCD 2a		NPRL3	chr16:143268	ENST00000399953	c.C980T	p.P327L	Missense	0.46
MCD_EEBB_91	M	5-9	35-39	MCD	FCD 2a		DEPDC5	chr22:32188751	NM_001242896	c.C715T	p.R239X	PTV	0.42
MCD_CCF_28	F	0-4	5-9	MCD	FCD 2b		TSC2	chr16:2103361	NM_000548	c.T244C	p.W82R	Missense	0.48
MCD_CCF_38	M	0-4	25-29	MCD	FCD 2b		MTOR	chr1:11217299	NM_004958	c.T4379C	p.L1460P	Missense	0.03
MCD_CCF_48	F	5-9	25-29	MCD	FCD 2b		DEPDC5	chr22:32161000	NM_001242896	c.G233C	p.R78P	Missense	0.37
MCD_CCF_48	F	5-9	25-29	MCD	FCD 2b		TSC2	chr16:2122364	NM_000548	c.G2220T	p.M740I	Missense	0.48
MCD_CCF_49	F	0-4	35-39	MCD	FCD 2b		MTOR	chr1:11188975	NM_004958	c.G5748T	p.W1916C	Missense	0.46
MCD_CCF_53	M	0-4	15-19	MCD	FCD 2b		MTOR	chr1:11169376	NM_004958	c.T7499A	p.I2500N	Missense	0.04
MCD_CCF_78	M	0-4	0-4	MCD	FCD 2b		DEPDC5	chr22:32200837	NM_001242896	c.C1153T	p.R385W	Missense	0.43
MCD_CCF_78	M	0-4	0-4	MCD	FCD 2b		NPRL3	chr16:188253	ENST00000399953	c.C14T	p.T5I	Missense	0.55
MCD_CCF_92	M	5-9	10-14	MCD	FCD 2b		MTOR	chr1:11187847	NM_004958	c.T6050C	p.I2017T	Missense	0.08
MCD_CCF_101	F	0-4	0-4	MCD	FCD 2b		MTOR	chr1:11184573	NM_004958	c.C6644A	p.S2215Y	Missense	0.03
MCD_CCF_102	M	5-9	15-19	MCD	FCD 2b		MTOR	chr1:11169377	NM_004958	c.A7498T	p.I2500F	Missense	0.04
MCD_CCF_102	M	5-9	15-19	MCD	FCD 2b		TSC1	chr9:135804196	NM_000368	c.C64T	p.R22W	Missense	0.42
MCD_EEBB_32	M	10-14	20-24	MCD	FCD 2b		NFI	chr17:29701091	NM_001042492	c.C8438T	p.T2813I	Missense	0.21
MCD_EEBB_67	M	20-24	30-34	MCD	FCD 2b		NFI	chr17:29677224	NM_001042492	c.G7345C	p.V2449L	Missense	0.40
MCD_EEBB_71	F	0-4	10-14	MCD	FCD 2b		MTOR	chr1:11188164	NM_004958	c.C5930A	p.T1977K	Missense	0.05
MCD_EEBB_80	M	5-9	15-19	MCD	FCD 2b		MTOR	chr1:11184573	NM_004958	c.C6644T	p.S2215F	Missense	0.03
MCD_EEBB_85	F	0-4	30-34	MCD	FCD 2b		PTEN	chr10:89623887	NM_001304717	c.180_181insAA	p.L61Nfs*2	PTV	0.49
MCD_EEBB_92	M	0-4	0-4	MCD	FCD 2b		MTOR	chr1:11174399	NM_004958	c.7276delinsCCCT	p.P2425_L2426insP	Missense	0.03
MCD_CCF_93	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	AKT3	chr1:243859016	NM_005465	c.G49A	p.E17K	Missense	0.08
MCD_CCF_94	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a / FCD 1a	PTEN	chr10:89720720	NM_000314	c.872dupA	p.N292Kfs*6	PTV	0.74

MCD_CCF_110	M	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	AKT3	chr1:243859016	NM_005465	c.G49A	p.E17K	Missense	0.13
MCD_EEBB_14	F		0-4	MCD	cMCD	HME / FCD 2a	MTOR	chr1:1184573	NM_004958	c.C6644A	p.S2215Y	Missense	0.10
MCD_EEBB_21	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	PIK3CA	chr3:178936091	NM_006218	c.G1633A	p.E545K	Missense	0.16
MCD_EEBB_26	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	PIK3CA	chr3:178952085	NM_006218	c.A3140T	p.H1047L	Missense	0.19
MCD_EEBB_28	M	0-4	0-4	MCD	cMCD	HME / FCD 2a	MTOR	chr1:1169377	NM_004958	c.A7498T	p.I2500F	Missense	0.03
MCD_EEBB_52	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	PIK3CA	chr3:178936082	NM_006218	c.G1624A	p.E542K	Missense	0.27
MCD_EEBB_57	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	AKT3	chr1:243859016	NM_005465	c.G49A	p.E17K	Missense	0.08
MCD_EEBB_57	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a	MTOR	chr1:11313993	NM_004958	c.C743T	p.T248I	Missense	0.47
MCD_CCF_32	M	0-4	0-4	MCD	cMCD	PMG / FCD 2a / FCD 1a	NPRL3	chr16:169168	ENST00000399953	c.G275A	p.R92Q	Missense	0.30
MCD_CCF_104	F	0-4	0-4	MCD	cMCD	PMG / FCD 2b	MTOR	chr1:11301647	NM_004958	c.A1504C	p.K502Q	Missense	0.09
MCD_CCF_104	F	0-4	0-4	MCD	cMCD	PMG / FCD 2b	TSC2	chr16:2135289	NM_000548	c.A4628G	p.H1543R	Missense	0.41
MCD_EEBB_10	M	10-14	25-29	MCD	cMCD	PMG / NH / FCD 2a / GG	NRAS	chr1:115256529	NM_002524	c.A182G	p.Q61R	Missense	0.13
MCD_EEBB_65	F	0-4	20-24	MCD	cMCD	PMG / NH / FCD 2a / DNET	NRAS	chr1:115256530	NM_002524	c.C181A	p.Q61K	Missense	0.24
MCD_EEBB_76	M	0-4	0-4	MCD	cMCD	PMG / FCD 2b	MTOR	chr1:11174399	NM_004958	c.7276delinsCCCT	p.P2425_L2426insP	Missense	0.04
MCD_EEBB_89	M	5-9	20-24	MCD	cMCD	PMG / FCD 1b	NFI	chr17:29483029	NM_001042492	c.C89A	p.T30K	Missense	0.03
MCD_EEBB_89	M	5-9	20-24	MCD	cMCD	PMG / FCD 1b	NFI	chr17:29483016	NM_001042492	c.G76T	p.G26X	PTV	0.46
MCD_CCF_27	F	0-4	5-9	MCD	TSC	FCD2b	TSC2	chr16:2130169	NM_000548	c.3402dupC	p.H1135Pfs*33	PTV	0.45
MCD_CCF_29	F	0-4	0-4	MCD	TSC	FCD 2b	TSC2	chr16:2121603	NM_000548	c.C1932A	p.C644X	PTV	0.46
MCD_CCF_55	M	0-4	5-9	MCD	TSC	FCD2b	TSC2	chr16:2136739	NM_000548	c.T4856C	p.F1619S	Missense	0.46
MCD_CCF_56	F	0-4	5-9	MCD	TSC	FCD2b	TSC2	chr16:2107157	NM_000548	c.826_827del	p.M276Vfs*6I	PTV	0.43

Legend to supplementary table 2: HS = Hippocampal sclerosis, MCD = Malformation of cortical development, LEAT = Low-grade epilepsy-associated tumor, FCD = Focal cortical dysplasia, MOGHE = mild MCD with oligodendroglial hyperplasia in epilepsy, HME = Hemimegalencephaly, PMG = Polymicrogyria, cMCD = complex MCD, TSC = tuberous sclerosis complex, MA = meningioangiomas, DNET = Dysembryoplastic neuroepithelial tumor, PXA = Pleomorphic xanthoastrocytoma, MVNT = multinodular vacuolated neuronal tumor, SEGA = Subependymal giant cell astrocytoma, PTV = Protein-truncating variant

Supplementary Table 5: Reported somatic CNV and CNN-LOH

Sample	Sex	Age at onset	Age at surgery	Lesion group	Pathology	Additional findings	Variant Position (hg19)	Region	Variant type	Included LFE genes	Size (Mbp)	Allelic fraction	Recurring	Samples w/ CNV
HS_EEBB_7	M	5-9	50-54	HS	HS Type 1		22:18520612-51304566	22q	CNN-LOH	<i>DEPDC5</i>	32.8	0.03	yes	5
HS_EEBB_81	F	0-4	25-29	HS	HS Type 1	FCD 3a	19:50401320-59128983	19q13.42-13.43	CNN-LOH		8.7	0.03	yes	2
HS_EEBB_17	M	20-24	25-29	HS	HS Type 2	FCD 3a	19:54462369-59128983	19q13.42-13.43	CNN-LOH		4.7	0.02	yes	2
HS_EEBB_55	F	15-19	45-49	HS	HS (NOS)		9:86179563-141213431	9q21.33-34.2	Loss	<i>TSC1</i>	55.0	0.03	yes	2
LEAT_EEBB_33	M	10-14	15-19	LEAT	DNET		6:0-171115067	6	Gain	<i>MYB</i>	171.1	0.01	yes	8
LEAT_EEBB_36	M	0-4	5-9	LEAT	DNET		7:138562547-140335570	7q34	Gain		1.8	0.20	yes	2
LEAT_EEBB_41	M	0-4	0-4	LEAT	DNET		8:0-38684853	8p	CNN-LOH	<i>FGFR1</i>	38.7	0.11	yes	2
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		19:44544237-59128983	19q13.31-13.4	Loss		14.6	0.05	no	1
LEAT_EEBB_49	F	30-34	30-34	LEAT	DNET		20:0-22746255	20p	Loss		22.7	0.03	no	1
LEAT_EEBB_55	M	20-24	25-29	LEAT	DNET		2:25568821-63939417	2p23.3-15	Gain		38.4	0.21	no	1
LEAT_EEBB_55	M	20-24	25-29	LEAT	DNET		2:0-25424397	2p25.3-23.3	Loss		25.4	0.26	no	1
LEAT_EEBB_55	M	20-24	25-29	LEAT	DNET		8:49729020-94305178	8q11.21-22.1	Loss	<i>MYBL1</i>	44.6	0.11	no	1
LEAT_EEBB_55	M	20-24	25-29	LEAT	DNET		13:28150993-115169878	13	Loss		87.0	0.26	yes	2
LEAT_EEBB_55	M	20-24	25-29	LEAT	DNET		15:23833737-60664030	15q11.2-22.2	Loss		36.8	0.05	no	1
LEAT_EEBB_75	M	5-9	10-14	LEAT	DNET		2:0-243199373	2	Gain		243.2	0.01	yes	3
LEAT_EEBB_75	M	5-9	10-14	LEAT	DNET		7:0-147731239	7	Gain	<i>BRAF</i>	147.7	0.02	yes	18
LEAT_EEBB_75	M	5-9	10-14	LEAT	DNET		7:138550994-140481402	7q34	Gain	<i>BRAF</i>	1.9	0.30	yes	2
LEAT_EEBB_75	M	5-9	10-14	LEAT	DNET		12:49424065-51343851	12q13.12	Gain		1.9	0.32	no	1
LEAT_EEBB_81	M	45-49	55-59	LEAT	DNET		8:0-42446238	8p	CNN-LOH	<i>FGFR1</i>	42.4	0.04	yes	2
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		4:0-191154276	4	Gain		191.2	0.12	yes	5
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		6:0-171115067	6	Gain	<i>MYB</i>	171.1	0.11	yes	8
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		7:0-159138663	7	Gain	<i>RHEB, BRAF</i>	159.1	0.12	yes	18
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		9:0-141213431	9	Gain	<i>TSC1</i>	141.2	0.12	yes	2
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		11:0-135006516	11	Gain		135.0	0.13	yes	5

LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		14:1.9e+07-107349540	14q	Gain		88.3	0.12	yes	2
LEAT_EEBB_104	M	5-9	15-19	LEAT	DNET		20:0-63025520	20	Gain		63.0	0.12	yes	10
LEAT_EEBB_105	F	35-39	35-39	LEAT	DNET		6:0-171115067	6	Gain	MYB	171.1	0.02	yes	8
LEAT_EEBB_105	F	35-39	35-39	LEAT	DNET		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.08	yes	18
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.20	yes	11
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.21	yes	18
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		11:0-135006516	11	Gain		135.0	0.20	yes	5
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPN11	133.9	0.20	yes	8
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		19:0-59128983	19	Gain		59.1	0.20	yes	5
LEAT_EEBB_1	F	10-14	15-19	LEAT	Ganglioglioma		20:0-63025520	20	Gain		63.0	0.19	yes	10
LEAT_EEBB_4	M	0-4	15-19	LEAT	Ganglioglioma		10:118766183-123216161	10q25.3-26.13	Loss		4.4	0.22	no	1
LEAT_EEBB_11	F	5-9	10-14	LEAT	Ganglioglioma		1:20142866-249250621	1	Gain	AKT3	229.1	0.03	no	1
LEAT_EEBB_11	F	5-9	10-14	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.03	yes	11
LEAT_EEBB_11	F	5-9	10-14	LEAT	Ganglioglioma		20:921971-63025520	20	Gain		62.1	0.07	yes	10
LEAT_EEBB_15	M	15-19	15-19	LEAT	Ganglioglioma	HS	9:0-141213431	9	Loss	TSC1	141.2	0.06	yes	3
LEAT_EEBB_16	M	5-9	20-24	LEAT	Ganglioglioma		3:0-56942973	3p26.3-14.3	Loss	NPRL2, RAF1	56.9	0.04	no	1
LEAT_EEBB_16	M	5-9	20-24	LEAT	Ganglioglioma		22:17725150-51304566	22q	Loss	DEPDC5	33.6	0.04	yes	4
LEAT_EEBB_32	F	20-24	20-24	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.29	yes	11
LEAT_EEBB_32	F	20-24	20-24	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.29	yes	18
LEAT_EEBB_32	F	20-24	20-24	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPN11	133.9	0.29	yes	8
LEAT_EEBB_40	F	10-14	25-29	LEAT	Ganglioglioma	HS Type I	19:0-59128983	19	Gain		59.1	0.18	yes	5
LEAT_EEBB_40	F	10-14	25-29	LEAT	Ganglioglioma	HS Type I	20:0-63025520	20	Gain		63.0	0.19	yes	10
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		21:15515843-48129895	21q	CNN-LOH		32.6	0.05	yes	2
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		22:17221495-51304566	22q	CNN-LOH	DEPDC5	34.1	0.06	yes	5
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		2:0-243199373	2	Gain		243.2	0.07	yes	3
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.05	yes	11

LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.04	yes	18
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPNI1	133.9	0.07	yes	8
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		14:24860592- 107349540	14q	Gain		82.5	0.06	yes	2
LEAT_EEBB_42	F	20-24	30-34	LEAT	Ganglioglioma		15:23226254- 102531392	15q	Gain		79.3	0.04	yes	3
LEAT_EEBB_48	M	25-29	40-44	LEAT	Ganglioglioma	HS Type I	4:58377516- 191154276	4q	Gain		132.8	0.02	no	1
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPNI1	133.9	0.05	yes	8
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		18:0-78077248	18	Gain		78.1	0.05	no	1
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		19:6547141- 59128983	19	Gain		52.6	0.05	yes	5
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		20:0-63025520	20	Gain		63.0	0.05	yes	10
LEAT_EEBB_63	M	10-14	15-19	LEAT	Ganglioglioma		13:21050575- 115169878	13	Loss		94.1	0.05	yes	2
LEAT_EEBB_70	F	15-19	20-24	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.05	yes	11
LEAT_EEBB_70	F	15-19	20-24	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.05	yes	18
LEAT_EEBB_70	F	15-19	20-24	LEAT	Ganglioglioma		11:0-135006516	11	Gain		135.0	0.11	yes	5
LEAT_EEBB_70	F	15-19	20-24	LEAT	Ganglioglioma		13:19307875- 115169878	13	Gain		95.9	0.11	yes	2
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		4:0-191154276	4	Gain		191.2	0.09	yes	5
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		6:0-171115067	6	Gain	MYB	171.1	0.06	yes	8
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.06	yes	18
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		9:0-141213431	9	Gain	TSC1	141.2	0.08	yes	2
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPNI1	133.9	0.06	yes	8
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		16:0-90354753	16	Gain	NPRL3, TSC2	90.4	0.08	yes	3
LEAT_EEBB_74	M	5-9	10-14	LEAT	Ganglioglioma		20:0-63025520	20	Gain		63.0	0.06	yes	10
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.03	yes	11
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		6:0-171115067	6	Gain	MYB	171.1	0.03	yes	8
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.03	yes	18
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		19:0-23207354	19p	Gain		23.2	0.12	no	1
LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		1:0-120110175	1p	Loss	MTOR	120.1	0.08	no	1

LEAT_EEBB_80	M	5-9	5-9	LEAT	Ganglioglioma		22:17897544-51304566	22q	Loss	DEPDC5	33.4	0.06	yes	4
LEAT_EEBB_85	M		30-34	LEAT	Ganglioglioma		4:0-191154276	4	Gain		191.2	0.04	yes	5
LEAT_EEBB_85	M		30-34	LEAT	Ganglioglioma		6:0-171115067	6	Gain	MYB	171.1	0.04	yes	8
LEAT_EEBB_87	F	10-14	50-54	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.04	yes	11
LEAT_EEBB_87	F	10-14	50-54	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.04	yes	18
LEAT_EEBB_87	F	10-14	50-54	LEAT	Ganglioglioma		12:0-133851895	12	Gain	KRAS, PTPN11	133.9	0.04	yes	8
LEAT_EEBB_87	F	10-14	50-54	LEAT	Ganglioglioma		20:0-63025520	20	Gain		63.0	0.02	yes	10
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		18:18570235-78077248	18q	CNN-LOH		59.5	0.01	no	1
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		21:20190260-48129895	21q	CNN-LOH		27.9	0.03	yes	2
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		4:0-191154276	4	Gain		191.2	0.02	yes	5
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		7:0-134639161	7	Gain		134.6	0.03	yes	18
LEAT_EEBB_98	M	15-19	15-19	LEAT	Ganglioglioma		11:0-135006516	11	Gain		135.0	0.04	yes	5
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		5:0-180915260	5	Gain		180.9	0.29	yes	11
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		6:0-171115067	6	Gain	MYB	171.1	0.33	yes	8
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.33	yes	18
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		10:0-135269349	10	Gain	PTEN	135.3	0.32	yes	3
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		15:20052938-102531392	15q	Gain		82.5	0.32	yes	3
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		20:0-63025520	20	Gain		63.0	0.32	yes	10
LEAT_EEBB_101	F	5-9	10-14	LEAT	Ganglioglioma		22:16000000-51304566	22q	Gain	DEPDC5	35.3	0.31	no	1
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	2:0-243199373	2	Gain		243.2	0.02	yes	3
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	3:0-188200897	3	Gain	NPRL2, RAF1, PIK3CA	188.2	0.02	no	1
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.27	yes	18
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	16:0-90354753	16	Gain	NPRL3, TSC2	90.4	0.02	yes	3
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	9:0-141213431	9	Loss	TSC1	141.2	0.36	yes	3
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	17:0-75075664	17	Loss	NFI	75.1	0.05	no	1
LEAT_EEBB_103	F	15-19	20-24	LEAT	Ganglioglioma	HS Type I	22:17223938-51304566	22q	Loss	DEPDC5	34.1	0.08	yes	4

LEAT_EEBB_110	M	5-9	15-19	LEAT	Angiocentric glioma		6:135543837-163969815	6q23.3-24.1	Loss		28.4	0.20	yes	2
LEAT_EEBB_46	M	10-14	20-24	LEAT	Angiocentric glioma		6:135521495-141454143	6q23.3-24.1	Loss	MYB	5.9	0.69	yes	2
LEAT_EEBB_19	F	15-19	15-19	LEAT	Desmoplastic Ganglioglioma		5:71661131-180915260	5q13.2-35.3	Loss		109.3	0.23	no	1
LEAT_EEBB_19	F	15-19	15-19	LEAT	Desmoplastic Ganglioglioma		9:73909871-86175639	9q21.12-21.32	Loss		12.3	0.22	no	1
LEAT_EEBB_19	F	15-19	15-19	LEAT	Desmoplastic Ganglioglioma		9:88234954-137530346	9q21.33-34.2	Loss	TSC1	49.3	0.23	yes	2
LEAT_EEBB_19	F	15-19	15-19	LEAT	Desmoplastic Ganglioglioma		22:23754578-51304566	22q	Loss	DEPDC5	27.5	0.22	yes	4
LEAT_EEBB_112	M	5-9	25-29	LEAT	IDA		9:0-141213431	9	Loss	TSC1	141.2	0.22	yes	3
LEAT_EEBB_112	M	5-9	25-29	LEAT	IDA		18:0-78077248	18	Loss		78.1	0.24	no	1
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	5:0-180915260	5	Gain		180.9	0.35	yes	11
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.35	yes	18
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	11:0-135006516	11	Gain		135.0	0.34	yes	5
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	12:0-133851895	12	Gain	KRAS, PTPN11	133.9	0.06	yes	8
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	13:19377679-115169878	13	Gain		95.8	0.06	yes	2
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	17:0-81195210	17	Gain	NFI	81.2	0.24	no	1
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	19:0-59128983	19	Gain		59.1	0.33	yes	5
LEAT_EEBB_50	M	25-29	25-29	LEAT	IDA	HS Type I	20:0-63025520	20	Gain		63.0	0.03	yes	10
LEAT_EEBB_113	M	0-4	44-49	LEAT	MVNT		5:0-180915260	5	Gain		180.9	0.02	yes	11
LEAT_EEBB_113	M	0-4	44-49	LEAT	MVNT		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.06	yes	18
LEAT_EEBB_102	F	5-9	10-14	LEAT	Pilocytic Astrocytoma		17:52121998-81195210	17q22-25.3	Gain		29.1	0.23	no	1
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		17:26851501-81195210	17q	CNN-LOH	NFI	54.3	0.12	yes	2
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		4:0-191154276	4	Gain		191.2	0.15	yes	5
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		6:0-171115067	6	Gain	MYB	171.1	0.06	yes	8
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.15	yes	18
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		10:0-135534747	10	Gain	PTEN	135.5	0.14	yes	3
LEAT_EEBB_95	F	5-9	34-39	LEAT	Pilocytic Astrocytoma		19:0-59128983	19	Gain		59.1	0.07	yes	5
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		5:0-180915260	5	Gain		180.9	0.10	yes	11



LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		7:0-65796278	7p22.3-q11.21	Gain		65.8	0.11	no	1
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		10:0-135534747	10	Gain	PTEN	135.5	0.12	yes	3
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		12:0-133851895	12	Gain	KRAS, PTPN11	133.9	0.12	yes	8
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		15:24148457- 102531392	15q	Gain		78.4	0.12	yes	3
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		16:0-90354753	16	Gain	NPRL3, TSC2	90.4	0.12	yes	3
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		20:0-63025520	20	Gain		63.0	0.12	yes	10
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		21:15463956- 48129895	21q	Gain		32.7	0.14	no	1
LEAT_EEBB_56	M	10-14	15-19	LEAT	PXA		7:65796279- 159138663	7q	Loss	RHEB, BRAF	93.3	0.24	no	1
LEAT_CCF_37	M	0-4	5-9	LEAT	TSC	SEGA	16:0-9806375	16p13.3	CNN-LOH	NPRL3, TSC2	9.8	0.03	yes	4
LEAT_CCF_37	M	0-4	5-9	LEAT	TSC	SEGA	7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.14	yes	18
LEAT_EEBB_17	F	0-4	5-9	LEAT	TSC	SEGA	16:0-16081737	16p13.3	CNN-LOH	NPRL3, TSC2	16.1	0.09	yes	4
MCD_CCF_62	F	5-9	5-9	MCD	FCD 2a	Hyaline astrocytic inclusions	1:146523045- 249250621	1q	Gain	AKT3	102.7	0.06	yes	2
MCD_CCF_62	F	5-9	5-9	MCD	FCD 2a	Hyaline astrocytic inclusions	16:47304567- 90354753	16q12.1-24.3	Loss		43.1	0.06	no	1
MCD_EEBB_68	M	5-9	40-44	MCD	FCD 2a		22:18009909- 49085205	22q	CNN-LOH	DEPDC5	31.1	0.04	yes	5
MCD_EEBB_75	M	0-4	10-14	MCD	FCD 2a		22:19183787- 51304566	22q	CNN-LOH	DEPDC5	32.1	0.04	yes	5
MCD_EEBB_94	F	0-4	0-4	MCD	FCD 2a		22:1.6e+07- 51304566	22q	CNN-LOH	DEPDC5	35.3	0.04	yes	5
MCD_EEBB_110	M	0-4	5-9	MCD	FCD 2a	Hyaline astrocytic inclusions	1:145723739- 249250621	1q	Gain	AKT3	103.5	0.08	yes	2
MCD_CCF_48	F	5-9	25-29	MCD	FCD 2b		9:71034203- 141213431	9q21.11-34.3	CNN-LOH	TSC1	70.2	0.09	no	1
MCD_CCF_48	F	5-9	25-29	MCD	FCD 2b		16:0-3367061	16p13.3	CNN-LOH	NPRL3, TSC2	3.4	0.05	yes	4
MCD_CCF_90	F	0-4	0-4	MCD	FCD 2b		7:0-159138663	7	Gain	RHEB, BRAF	159.1	0.05	yes	18
MCD_EEBB_104	F		15-19	MCD	FCD 2b		4:93918343- 191154276	4q22.2-35.2	CNN-LOH		97.2	0.02	no	1
MCD_CCF_71	F	0-4	0-4	MCD	cMCD	PMG / NH	1:203644628- 234525940	1q32.1-42.2	Gain		30.9	0.06	no	1
MCD_CCF_94	F	0-4	0-4	MCD	cMCD	HME / PMG / FCD 2a / FCD 1a	10:75324903- 135534747	10q22.2-26.3	CNN-LOH	PTEN	60.2	0.15	no	1
MCD_CCF_104	F	0-4	0-4	MCD	cMCD	PMG / FCD 2b	16:0-12353187	16p13.3	CNN-LOH	NPRL3, TSC2	12.4	0.04	yes	4
MCD_EEBB_89	M	5-9	20-24	MCD	cMCD	PMG / FCD 1b	17:28305017- 81195210	17q	CNN-LOH	NF1	52.9	0.06	yes	2

Legend to supplementary table 3: LFE = lesional focal epilepsy, CNV = Copy number variant, LEAT = Low-grade epilepsy-associated tumor, MCD = Malformation of cortical development, HS = Hippocampal sclerosis, DNET = Dysembryoplastic neuroepithelial tumor, IDA = Isomorphic diffuse astrocytoma, PXA = Pleomorphic xanthoastrocytoma, MVNT = multinodular vacuolated neuronal tumor, SEGA = Subependymal giant cell astrocytoma, TSC = Tuberous sclerosis complex, FCD = Focal cortical dysplasia, HME = Hemimegalencephaly, cMCD = complex MCD, PMG = Polymicrogyria, CNN-LOH = Copy number neutral loss of heterozygosity